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Iron and zinc may interact in micronutrient supplements and thereby decrease eﬃcacy. We investigated interactive eﬀects of
combined zinc and iron supplementation in a randomized controlled trial conducted in 459 Guatemalan women. Four groups
weresupplementedfor12weeks:(1)weeklyironandfolicacid(IFA);(2)weeklyIFAand30mgzinc;(3)dailyIFA;(4)dailyIFAand
15mg zinc. Eﬀects were assessed by generalized linear regression. Baseline hemoglobin (Hb) concentration was 137.4 ± 15.5g/L,
13% were anemic and 54% had zinc deﬁciency. Hb cconcentrations were similar by supplement type, but Hb concentrations
improved signiﬁcantly in anemic women at baseline (increase of 21.8g/L). Mean percentage changes in serum ferritin were
signiﬁcantly higher in daily compared to weekly supplemented groups (86% versus 32%). The addition of zinc to IFA supplements
had no signiﬁcant impact on iron or zinc status. In conclusion, adding zinc to IFA supplements did not modify eﬃcacy on iron
status or improve zinc status, but daily supplementation was more eﬃcacious than weekly in improving iron stores.
1.Introduction
Women of reproductive age (WRA) in poor countries are
at high risk for micronutrient deﬁciencies, particularly iron
and zinc. WHO estimates that 30.2% of nonpregnant and
41.8% of pregnant women suﬀer from anemia, much of it
due to iron deﬁciency [1–3]. Information on zinc deﬁciency
in WRA is limited. Some 1.2 billion people worldwide are at
risk of inadequate zinc intake and presumably many are zinc
deﬁcient [4]. Both iron and zinc deﬁciencies have adverse
consequences for human health. Iron deﬁciency results
in anemia, impaired psychomotor development, reduced
physical and work capacity, impaired immunity, and adverse
pregnancy outcomes [5]. Zinc deﬁciency is associated with
fertility reduction [6], poor pregnancy outcomes [7], mental
and behavioral changes [8], impaired immunity, increased
morbidity and mortality [9], and perhaps linear growth
retardation [10, 11].
Several strategies have been implemented to address iron
andzincdeﬁciency,includingsupplementationandfoodfor-
tiﬁcation. One approach is through combined zinc and iron
supplementation. However, there is concern about potential
interactions between these two trace minerals. Although
some pathways are unique, iron and zinc have many similar
absorption and transport mechanisms and may therefore
compete for absorption [12, 13]. Several studies examined
the eﬃcacy of supplementation with iron and zinc, but most
were conducted in children and involved only daily doses.
Little is known regarding the inﬂuence of zinc on the eﬃcacy
of iron supplementation on a weekly basis, particularly in
WRA. One study, in Bangladeshi infants [14], examined
weekly supplementation of zinc, iron, and of combined2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
iron and zinc. Results showed that weekly provision of
both iron and zinc supplementation did not modify the
eﬀect of each nutrient when given alone. Recently, a meta-
analysis examined the impact of zinc supplementation on
biochemical indicators of iron and zinc [10]. This paper,
however, did not quantify the eﬀects of adding zinc to iron
comparedtoironaloneonironandzincstatus.Theobjective
of this study is to investigate the eﬃcacy of IFA supplements
provided daily or weekly with and without zinc on iron and
zinc status in a randomized control trial (RCT) carried out
in Guatemalan WRA.
2. Methods
The study design, sample size calculation, data collection,
and characteristics of the Guatemalan RCT have been
described in detail elsewhere [15]. Brieﬂy, 459 nonpregnant,
nonlactating women aged 15–49 years from the village of
Concepci´ on Chiquirichapa located in the western highlands
of Guatemala were recruited. These women were randomly
assigned to receive one of four supplements: (1) weekly
120mg iron with 30mg zinc, (2) weekly 120mg iron, (3)
daily 60mg iron with 15mg zinc, and (4) daily 60mg iron.
Iron and zinc were provided as ferrous sulphate and zinc
sulphate, respectively. All supplements also contained folic
acid (FA) (the weekly arms had either 5000 or 2800μga n d
thedailyarms400or200μg,resp.)andvitaminB-12(16.8μg
for the weekly arms or 2.4μg for the daily arms). Trained
ﬁeld workers from the community visited each woman 7
days a week to deliver and observe the ingestion of the
supplements (two-three hours after a meal) for the entire
12-week duration of supplementation. All women received
7 pills per week. The weekly dose groups received 6 placebos
and 1 active pill on the third day of the week. Daily records
were kept to track the participants’ health and compliance.
The trial was registered in the US NIH Clinical Trial Registry
(identiﬁcation number NCT003994862).
Dietary intake data at baseline were collected by means
of a semiquantitative food frequency questionnaire; socio-
demographic information was also collected at baseline [15].
The eﬀect of supplementation on folate and homocysteine
status was reported previously [15]. Here we assess the
impact of supplements on iron and zinc status. Hb, serum
ferritin, C-reactive protein (CRP), and serum zinc were
measured pre- and post-supplementation. A capillary blood
sample was obtained from a ﬁnger prick to measure Hb
concentrations using a B-Hemoglobin Analyzer. Venous
blood was collected for measuring serum ferritin and CRP
using a Nephelometric immunoassay reactive kit and for
determining serum zinc using a ﬂame atomic absorption
spectroscopy method [16]. Venous blood was collected after
an overnight fast using trace mineral free syringes; tubes
were centrifuged within an hour at 3,000rpm for 10 minutes
at 4◦C. The serum was separated and stored at −70◦Ca t
the Institute of Nutrition of Central America and Panama
(INCAP) in Guatemala City until analysis at the National
Institute of Public Health (NIPH), Cuernavaca, Mexico. The
time lag between the last consumption of supplement and
the blood draw was similar for weekly and daily groups
(2.46 ± 1.15 days versus 2.50 ±1.02 days, P>0.05).
Since willingness to provide a blood sample was a
criterion, blood samples were available for all 459 subjects
at baseline (Figure 1). Of these, 422 (92%) ﬁnished the trial;
reasons for loss to followup were similar across groups,
but the daily iron/zinc group had a higher dropout rate
compared to the other groups (P = 0.02). A total of 369
women or 88% also provided an endline blood sample (i.e.,
52 women refused). Analyses were performed based on these
369 subjects (88 in the weekly iron and zinc group, 97 in the
weekly iron group, 84 in the daily iron and zinc group, and
100 in the daily iron group) or 80% of those randomized
at baseline. Subjects included in the analyses had similar
baseline characteristics compared to subjects not included
(P>0.05, results not shown).
Since the women lived 2600 m above sea level, Hb
was adjusted for altitude using an exponential curve of Hb
concentration by altitude described by Cohen and Haas [17].
Data were checked for normality using the Kolmogorov-
Smirnov test of normality. Log transformation was used
to normalize the distribution of serum ferritin. The eﬀect
of treatment on Hb, serum ferritin, and zinc was assessed
using a generalized linear regression model (SAS Proc Mixed
procedures) assuming unstructured correlation to account
for the correlation among the repeated observations for a
given subject [18], using treatment as a ﬁxed factor and
time as a covariate. The between-subjects factor was four
treatment types and the within-subjects factor was treatment
eﬀects (from start to ﬁnish of supplementation). Between-
group diﬀerences in treatment eﬀect would be indicated
by a signiﬁcant interaction between treatment eﬀect and
treatment type. This is obtained by ﬁtting the model below:
Outcome = β0+β1 ×time +β2 ×treatment+β3
×time × treatment+Bi×other covariates.
(1)
The model takes baseline values into account in estimat-
ing supplement eﬀects. We investigated further whether the
eﬀects of supplementation varied depending on initial Hb,
serum ferritin, and serum zinc status. Anemia was deﬁned
as Hb value <120g/L, insuﬃcient iron stores were deﬁned as
serum ferritin <20μg/L, and depleted iron stores as serum
ferritin <12μg/L; zinc deﬁciency was deﬁned as serum zinc
<10.7μmol/L.
Serum CRP concentrations were low (3.5% of values
were >10mg/L), similar at baseline and endline and across
groups and their inclusion in the model (as dichotomous
variables indicating >5mg/L at baseline and endline or
alternatively, >10mg/L; or as linear and quadratic terms to
account for nonlinearity) had only a trivial inﬂuence on
estimates of the eﬀect of supplementation on serum ferritin
values and did not inﬂuence the zinc results (results not
shown). Thus, for the sake of parsimony, we did not include
CRP in the models.
All statistical tests were two-tailed, and diﬀerences were
considered signiﬁcant at P<0.05. SAS software, version 9.1
was used for statistical analysis [19].J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: Flow chart describing participation of subjects in the study.
3. Results
There were no signiﬁcant diﬀerences in selected character-
istics across the four treatment groups at baseline (Table 1).
Levels of Hb, serum ferritin, and zinc before and after the
intervention by group are shown in Table 2. The baseline Hb
concentration was 137.4±15.5g/L. Mean Hb concentrations
were not signiﬁcantly diﬀerent across the 4 treatment groups
at baseline or endline. However, the changes in Hb were
strongly related to the initial Hb concentration (r =− 0.65;
P<0.001). Overall Hb concentrations increased by 21.8g/L
(95% CI: 17.5, 26.2) among anemic women but decreased
by 4.8g/L (−6.5; −3.2) among nonanemic women (data not
shown).
Baseline ferritin concentrations did not diﬀer across
groups (P = 0.98) (Table 2). Ferritin levels increased sig-
niﬁcantly in all 4 supplementation groups after 12 weeks
of supplementation (P< 0.001). There were diﬀerences
between groups in treatment eﬀects (P = 0.0006). The two
groups receiving daily supplementation had signiﬁcantly
higher ferritin concentrations than those receiving weekly.
Ferritin levels increased by 86% (95% CI: 67, 108) or
31.7μg/L in daily groups compared to 32% (95% CI: 18, 47)
or 7.6μg/L in weekly groups. No signiﬁcant diﬀerences were
foundinferritinlevelsinthedailygroupsbetweenthosewith
or without zinc (P = 0.94) or in the weekly groups between
those with or without zinc (P = 0.38).
The prevalence of anemia before supplementation was
13% and that of insuﬃcient iron stores was 19.7%. There
was no diﬀerence in the proportion of anemia at baseline
and endline by supplement type (Table 3). The prevalence of
iron insuﬃciency and depletion decreased signiﬁcantly but
was similar across the 4 groups. Overall iron insuﬃciency
d e c r e a s e df r o m1 9 . 7t o6 . 6 %( P<0.001) and iron depletion
d e c r e a s e df r o m1 1 . 5t o2 . 7 %( P<0.001).
Theinitialserumzincconcentrationwas10.5±2.1μmol/
L. There were no signiﬁcant diﬀerences across the 4 groups
at baseline or endline. Serum zinc concentrations did not
change in any of the intervention groups after supplemen-
tation (P = 0.55) (Table 2). Zinc deﬁciency was observed in
54.4% of women. The prevalence of zinc deﬁciency did not
change after supplementation in any of the four groups (P =
0.52) (Table 3).
4. Discussion
In the present study, women randomly assigned to receive
daily or weekly Fe-FA supplements with or without zinc.4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
Table 1: Selected baseline characteristics of the four treatment groups.
Characteristics
Treatment groups
Weekly Fe + Zn
(n = 88)
Weekly Fe
(n = 97)
Daily Fe + Zn
(n = 84)
Daily Fe
(n = 100) P value
Age (years) 31.0 ± 9.41 31.4 ±9.03 0 .2 ±8.93 1 .6 ±10.10 . 7 5 4
Education (years) 5.5 ±3.86 .0 ±4.36 .2 ±3.85 .7 ±3.50 . 6 6
Socioeconomic status
Low 29 (33.3)2 35 (36.1) 34 (41.0) 32 (32.3) 0.385
Medium 31 (35.6) 24 (24.7) 25 (30.1) 38 (38.4)
High 27 (31.0) 38 (39.2) 24 (28.9) 29 (29.3)
Weight (kg) 55.2 ±9.65 4 .9 ±8.95 5 .4 ±10.75 3 .5 ±10.00 . 5 8
Height (cm) 145.1 ±4.4 145.2 ±4.7 145.1 ±5.1 144.7 ±4.40 . 8 9
Body mass index (kg/m2)2 6 .2 ±4.32 6 .1 ±4.32 6 .2 ±4.42 5 .5 ±4.10 . 6 1
Compliance (%) 98.8 ±1.99 8 .9 ±2.49 9 .0 ±1.69 9 .0 ±2.90 . 9 7
Dietary intake
Folate (μg) 3843 (292–524) 370 (252–485) 340 (246–540) 364 (281–483) 0.496
Vitamin B-12 (μg) 2.0 (0.7–4.1) 1.7 (0.8–3.9) 2.1 (0.7–3.2) 1.4 (0.7–3.0) 0.51
Vitamin B-6 (mg) 1.1 (0.8–1.4) 1.1 (0.7–1.5) 1.0 (0.8–1.4) 1.1 (0.7–1.4) 0.75
Iron (mg) 15.0 (11.3–21.5) 13.9 (9.7–18.1) 13.5 (10.3–17.7) 13.8 (10.7–17.5) 0.27
Zinc (mg) 9.2 (7.1–12.3) 9.2 (6.9–12.0) 9.1 (7.1–11.4) 8.6 (7.4–11.7) 0.97
Energy (kJ) 6732 (5749–8916) 6732 (5448–8477) 6661 (5594–8602) 6945 (5494–8184) 0.89
1Mean ± S Df o ra g e ,e d u c a t i o n ,h e i g h t ,w e i g h t ,B M I ,a n dc o m p l i a n c e .
2n (%) for SES.
3Median (interquartile range) for dietary intake.
4ANOVA test for age, education, height, weight, BMI, and compliance.
5Chi-square test for categorical variables.
6Kruskal-Wallis test for dietary intake.
Table 2: Hemoglobin, serum ferritin, and serum zinc concentrations in women before and after daily or weekly supplementation for
12weeks (n = 369).
Treatment groups Baseline Endline Diﬀerence
Hemoglobin, g/L n Mean1(95% CI) Mean1 (95% CI) Mean3 (95% CI)
Weekly Fe+ Zn 88 137.6 (134.3, 140.8) 135.5 (132.6, 138.4) −2.1( −5.8, 1.6)
Weekly Fe 97 138.7 (135.6, 141.8) 137.8 (135.0, 140.6) −0.9( −4.5, 2.6)
Daily Fe+ Zn 84 136.4 (133.0, 139.7) 135.3 (132.3, 138.3) −1.0( −4.8, 2.7)
Daily Fe 100 137.0(133.9, 140.0) 135.9 (133.2, 138.6) −1.1( −4.5, 2.4)
Serum ferritin, μg/L Mean2 (95% CI) Mean2 (95% CI) Mean3 (95% CI)
Weekly Fe+ Zn 88 40.1 (32.0, 50.4) 52.1 (44.5, 61.1) 29.9% (10.6, 52.6)4
Weekly Fe 97 41.2 (33.2, 51.2) 55.5 (47.6, 64.6) 34.6% (15.4, 57.0)4
Daily Fe+ Zn 84 39.0 (30.8, 49.3) 74.6 (63.2, 88.0) 91.2% (61.9, 125.9)5
Daily Fe 100 41.5 (33.6, 51.4) 75.8 (65.2, 88.2) 82.6% (57.0, 112.4)5
Serum zinc, μmol/L Mean1 (95% CI) Mean1 (95% CI) Mean3 (95% CI)
Weekly Fe+ Zn 88 10.0 (9.5, 10.4) 10.4 (9.9, 10.8) 0.4 (−0.2, 1.0)
Weekly Fe 97 10.5 (10.1, 10.9) 10.5 (10.1, 11.0) 0.0 (−0.5, 0.6)
Daily Fe+ Zn 84 10.9 (10.4, 11.3) 10.8 (10.3, 11.2) −0.1 (−0.7, 0.5)
Daily Fe 100 10.7 (10.3, 11.1) 10.6 (10.2, 11.0) −0.1 (−0.7, 0.4)
1Least square mean (95% CI) from generalized linear model (Proc Mixed).
2Geometric mean (95% CI).
3Mean percentage (95% CI) diﬀerence between endline and baseline values.
4,5Values in column with superscripts without a common number diﬀer signiﬁcantly, P<0.05.J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
Table 3: Anemia, iron, and zinc deﬁciency in women before and
after daily or weekly supplementation for 12week.
Treatment groups Baseline
(Percent)
Endline
(Percent)
Anemia (Hb <120g/L)
Overall 48(13.0) 53(14.5)
Weekly Fe+ Zn 13 (14.8) 16 (18.4)
Weekly Fe 13 (13.4) 13 (13.7)
Daily Fe+ Zn 13 (15.5) 12 (14.5)
Daily Fe 9 (9.0) 12 (12.0)
Insuﬃcient iron stores (serum ferritin <20μg/L)
Overall 72 (19.7)1 24(6.6)2
Weekly Fe+ Zn 20 (22.7)1 9 (10.2)2
Weekly Fe 21 (21.9)1 8 (8.3)2
Daily Fe+ Zn 16 (19.3)1 4 (4.8)2
Daily Fe 15 (15.2)1 3 (3.0)2
Depleted iron stores (serum ferritin <12μg/L)
Overall 42 (11.5)1 10(2.7)2
Weekly Fe+ Zn 11 (12.5)1 5 (5.7)2
Weekly Fe 11 (11.5)1 1 (1.0)2
Daily Fe+ Zn 8 (9.6)1 2 (2.4)2
Daily Fe 12 (12.1)1 2 (2.0)2
Zinc deﬁciency (serum zinc <10.7μmol/L)
Overall 198 (54.4) 207(56.9)
Weekly Fe+ Zn 56 (63.6) 53 (60.2)
Weekly Fe 51 (53.7) 61 (64.2)
Daily Fe+ Zn 42 (50.6) 44 (53.0)
Daily Fe 49 (50.0) 49 (50.0)
1,2Values in column with superscripts without a common number diﬀer
signiﬁcantly, P<0.05.
Neither daily nor weekly supplementation changed Hb
concentrations, and the addition of zinc did not inﬂuence
Hb concentrations. However, Hb concentrations improved
signiﬁcantly in women who were anemic at baseline by an
average of 21.8g/L. For serum ferritin, signiﬁcant between-
and within-group changes were noted. After supplementa-
tion, daily groups showed a much greater increase in serum
ferritin concentrations than the weekly groups, suggesting
that daily iron supplementation was more eﬃcacious than
weekly supplementation in improving serum ferritin con-
centrations. Ferritin concentrations improved by 86% (or
31.7μg/L) in the daily supplement groups compared with
32% (or 7.6μg/L) in the weekly groups. The addition of zinc
to supplements containing iron had no inﬂuence on serum
ferritin.
Although daily or intermittent iron supplementation,
with and without zinc, signiﬁcantly increased serum ferritin
concentration, it did not reduce the percentage of anemic
women. One possible explanation is that iron deﬁciency
may be only one of several causes of anemia. Mean Hb
concentrations improved signiﬁcantly in women who were
anemic at baseline by 21.8g/L, but this increase was not large
enough to reduce the prevalence of anemia.
Our ﬁndings showed that adding zinc to supplements
containing iron did not inﬂuence iron status but also did
not improve zinc status in WRA. Therefore, adding zinc to
IFA supplements may not be an optimal way to improve
zinc status in women. The addition of zinc to IFA may have
other beneﬁts for women, but there is limited information.
Findings from previous meta-analyses indicate that maternal
zincsupplementationresultedina14%reductioninpreterm
delivery but had no signiﬁcant impact on infant’s birth
weight nor on other pregnancy outcomes [20]. In a study
in Peru [21], 1295 mothers were assigned randomly to
receive prenatal supplements containing 60mg iron and
250μg FA, with or without 15mg zinc, beginning at 10–
24weeks of gestation. Findings from this study suggested
that adding zinc to IFA tablets did not aﬀect the duration
of pregnancy, size at birth, or developmental outcomes in
Peruvian children when assessed at 4.5 y of age [22]b u t
did improve postnatal growth [23]. A study in Ghana found
no diﬀerence in the mean weight of newborns of women
receiving a combined supplement of zinc and iron compared
to those of women receiving iron alone [24]. In a trial in
Nepal [25], 4926 pregnant women were allocated at random
to ﬁve regimens: daily supplements of FA, IFA, IFA with zinc,
multiple micronutrients, or vitamin A alone (control). The
addition of zinc to IFA reduced the eﬃcacy of IFA on birth
weight; the mean birth weight was 53g (0g to 108g) lower
in the IFA plus zinc group compared to the IFA group. Also,
there was no diﬀerence in the proportion of preterm births
between these two groups [25]. Finally, fetal loss and infant
mortality did not diﬀer between the groups who received
IFA only and IFA with zinc [26, 27]. Thus, adding zinc to
IFA supplements for women needs to be reconsidered since
it appears to not beneﬁt biochemical indicators or functional
indicators. More studies that assess the impact of combined
iron and zinc on functional status are needed to provide
scientiﬁc evidence for public health policy. Ultimately, the
public health beneﬁt of adding zinc to iron supplements
given to women depends on the baseline characteristics of
speciﬁcpopulationsandontherelativebeneﬁtsofimproving
iron and zinc status.
Possible reasons for the lack of an eﬀect of adding zinc
to iron on zinc status in WRA include the negative eﬀect of
iron on the absorption of zinc. Unfortunately, the lack of
a group that received zinc but no iron in the Guatemalan
RCT does not allow us to test this possibility. A review by
Solomons(1986)reportedthatcompetitiveinhibitionofzinc
uptake byironcanoccuratiron: zinc ratios of2:1or greater.
The ratio of iron: zinc in the supplements in most studies in
women is 4:1 while that ratio in most studies in children
is 1:1. In addition, ﬁndings from several studies suggest
that iron may have deleterious eﬀects on zinc metabolism
in women. A signiﬁcant reduction in zinc absorption was
reported when iron was taken with zinc in pregnant [28, 29]
and lactating [30] women. In nonpregnant women, oral iron
given with zinc impaired bioavailability of zinc [31, 32]. In
women, iron is often provided in combination with folic
acid.Thereisconcernthatfolicacidsupplementsmayimpair
zinc absorption [29, 33], possibly by forming an insoluble
chelate in the lumen [33] or by a mutually inhibitory eﬀect6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
of zinc and folate on intestinal transport mechanisms [34].
However, subsequent studies failed to conﬁrm the inhibitory
eﬀect of folate on zinc absorption [35] or on zinc status [36–
38]. Another possible but unlikely explanation for the lack
of eﬀect of zinc supplementation on serum zinc levels may
be that the dose of zinc used was insuﬃcient; we used a
dose that was twice the RDA [39]. Although several studies
have been carried out to assess the interaction between iron
and zinc, almost all of them used daily supplementation. To
our knowledge, the Guatemalan study is the ﬁrst RCT to
investigate the inﬂuence of zinc on iron eﬃcacy of weekly
doses in women. The only other weekly dose study was
conducted in Bangladeshi infants [14] who were assigned to
receive weekly supplementation of 1mg riboﬂavin (control),
20mg iron, 20mg zinc, or both for 6 months. Findings from
that study were that the addition of zinc to weekly iron
supplementation improved children’s zinc status but had no
diﬀerential eﬀect on iron status compared to iron alone.
The main strength of our study is the RCT design; other
strengths include the demonstration that randomization was
eﬀective, the direct observation of supplement intakes, and
the careful standardization and high quality of measure-
ments. While only 80% of women who were randomized at
baseline were included in the analyses, those not included
did not diﬀer from those included in terms of baseline
characteristics. Because of ethical concerns, women with
severe anemia (Hb < 70g/L) at baseline were treated and
excluded from the trial. Thus, the true prevalence of anemia
in the population is higher than the prevalence reported
in the study (13%). If severely anemic women had been
included in the study, the average eﬀect of supplementation
might have been larger. A limitation is the absence of a
placebo group; hence, we cannot exclude the possibility that
community-wide dietary improvements coincided with the
beginning of supplementation. This would appear highly
unlikely. Also, the lack of a zinc only group does not allow
us to fully assess the interaction between iron and zinc.
AnotherlimitationoftheGuatemalanRCTisthatitprovided
nutrients other than iron and zinc. This study was designed
primarily to test the relative impact of daily versus weekly
folic acid (FA) supplements, with two levels of doses for each
[15]. The main conclusion of the study was that weekly FA
(either high or low dose) may be as eﬃcacious as daily sup-
plementation (either high or low dose) in improving serum
folate levels. Thus, because of a similar response across all
groups, we believe that the folic acid in the supplements did
not inﬂuence the diﬀerential responses found across groups.
The supplements also contained vitamin B-12. Both weekly
groups received 16.8μg and both daily groups received
2.4μg. It was found that daily supplementation improved
serum B-12 signiﬁcantly while weekly supplementation had
no eﬀect. Because the key comparisons we make in our RCT
are between daily supplements with iron versus iron and
zinc or between weekly iron supplements with iron versus
iron and zinc, vitamin B-12 is not a factor in interpreting
these diﬀerences. On the other hand, B-12 would be an
issue in comparisons of any weekly to any daily iron/zinc
group. Finally, another possible limitation of our study is
that we included only CRP which captures the eﬀects of
inﬂammation early in the acute phase response; it would
have been appropriate to have also included alpha-1-acid
glycoprotein (AGP) to capture later stages of inﬂammation
[40]. Study women had low levels of CRP and these levels
did not inﬂuence the estimation of supplement eﬀects. CRP
values were similar across groups at baseline and endline;
we would expect other unmeasured, potential confounders,
such as AGP, to have also been balanced across groups. For
thesereasons,wethinkitisunlikelythattheomissionofAGP
clouds the interpretation of our results.
5. Conclusion
Both daily and weekly supplementations were eﬃcacious in
improving Hb concentration in anemic women. However,
daily supplementation was more eﬃcacious than weekly
in improving ferritin levels. The combined Fe-Zn supple-
mentation was as eﬀective as iron alone in improving iron
status but not eﬀective in improving zinc status. Other
approaches must be considered to control zinc deﬁciency in
this population.
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